权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Involvement of RUNX1 in Megakaryocytic Differentiation

RUNX1 参与巨核细胞分化

基本信息

批准号：
7622807
负责人：
Adam N. Goldfarb
金额：
$ 26.57万
依托单位：
UNIVERSITY OF VIRGINIA
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-04-23 至 2010-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7622807
关键词：
Acute Megakaryocytic Leukemias Alleles Amino Acids Binding Biochemical Genetics Biological Assay Biological Models Blood Platelets Chimera organism Clinical Data Complex Critical Pathways DNA Binding Data Defect Development Differentiation and Growth Disease Dissection Down Syndrome Down-Regulation Elements Erythro Erythroid Genes Genetic Growth Hematopoietic Hemorrhage Human Hypertrophy Knock-out Maps Marrow Mediating Megakaryocytes Megakaryocytopoieses Modeling Molecular Mus Muscle Pathway interactions Phenotype Phosphorylation Phosphorylation Site Phosphotransferases Physiological Production Protein Isoforms RNA RUNX1 gene Recruitment Activity Role Signal Transduction Site Somatic Mutation TP53 gene Testing Zebrafish abstracting human GATA1 protein human MPP1 protein human disease in vivo mouse model mutant promoter therapy design transcription factor

项目摘要

Project Summary/Abstract This application is to continue studies on the cross-talk between the transcription factors RUNX1 and GATA-1 in megakaryocytic differentiation. Transcriptional pathways that dictate megakaryocyte differentiation remain poorly characterized but will most likely provide important targets in the design of treatments for platelet production defects and for megakaryocytic leukemias. Biochemical, genetic, and clinical data all strongly support the coexistence of GATA-1 and RUNX1 in a common molecular pathway critical for normal megakaryocytic development. By contrast, the related factor GATA-2 lacks transcriptional cooperation with RUNX1 and cannot compensate for loss of GATA-1 in megakaryopoiesis in vivo. Functional mapping of GATA-1/GATA-2 chimeras has identified a 67 amino acid segment in the GATA-1 amino terminus critical for transcriptional cooperation with RUNX1. Mapping within RUNX1 has indicated requirements for DNA binding by the RUNT domain and for S/TP phosphoacceptor sites within the carboxy terminal region, particularly S400. Importantly, GATA-1 promotes hyperphosphorylation of RUNX1, and GATA-1/GATA-2 chimeras that lack transcriptional synergy with RUNX1 fail to induce RUNX1 hyperphosphorylation. Pharmacologic and molecular screens have identified Cdk9 as the kinase critical for transcriptional cooperation of RUNX1 and GATA-1. Indeed, GATA-1 recruits Cdk9 to RUNX1 transcriptional complexes, promoting phosphorylation of RUNX1 and associated factors. Interestingly, GATA-2 also binds Cdk9 but induces the downregulation of the Cdk9 p55 isoform. Cdk9 has been shown to participate in transcriptional elongation, cellular hypertrophy, and induction of RUNX1 expression during zebrafish hematopoietic ontogeny. In our unpublished data, inhibition of Cdk9 causes blockade of primary human megakaryocytic differentiation. In our mouse model, a synthetic lethal interaction exists between Cdk9 inhibition and GATA-1 deficiency. In particular, the GATA-1Lo strain, with a megakaryocte-specific deficit in GATA-1 expression, uniquely responds to Cdk9 inhibition by developing a fulminant but reversible megakaryoblastic proliferative disorder. This distinctive phenotype recalls a reversible human disease, the transient megakaryocytic proliferative disorder of Down syndrome, associated with somatic mutations of GATA-1. We also provide in vivo genetic evidence for GATA-1-RUNX1 megakaryocytic cooperation: deletion in mice of a single RUNX1 allele on a GATA-1Lo background causes spontaneous muscle bleeds and marrow dysmegakaryopoiesis. We therefore postulate: a) that GATA-1 promotes the recruitment of active Cdk9 to RUNX1 complexes, leading to RUNX1 activation, enhanced transcriptional elongation of megakaryocyte genes and consequent acquisition of a ¿hypertrophic¿ megakaryocyte phenotype, b) that GATA-2 fails to recruit active Cdk9 because of its induction of Cdk9 p55 downregulation, and c) that in vivo defects in this pathway contribute to megakaryocyte proliferative disorders and dysmegakaryopoiesis. Aim I will test this model through a molecular dissection of GATA-1 mediated Cdk9 signaling to RUNX1. Aim II will further explore the model in murine model systems of megakaryopoiesis, employing GATA-1 and RUNX1 knockout strains.

项目总结/文摘